Overdose deaths remain a serious public health problem, and researchers have been searching for new tools to reduce that risk. One unexpected area of interest is a class of peptide-based compounds known as glucagon-like peptide-1 receptor agonists, or GLP-1 receptor agonists. These molecules were originally studied in the context of blood sugar regulation, but preclinical research suggested they might also affect reward and craving pathways in the brain.
A peer-reviewed study published in The Journal of Clinical Psychiatry examined health records from the Veterans Health Administration to explore whether GLP-1 receptor agonists were associated with lower rates of all-cause overdose among veterans who had both type 2 diabetes and opioid use disorder. The researchers used a method called target trial emulation, which is a rigorous observational approach designed to mimic the structure of a randomized controlled trial as closely as possible using existing data.
The findings are nuanced, and the authors are careful to note that randomized controlled trials are still needed. But the study adds to a small and growing body of evidence that GLP-1 receptor agonists may be worth investigating in the context of substance use disorders.
How the study was designed
Researchers pulled data from the Veterans Health Administration covering the period from January 2020 through December 2024. They focused on veterans who had been diagnosed with both type 2 diabetes and opioid use disorder, two conditions that frequently appear together and each carry serious health risks on their own.
The study compared veterans who started either semaglutide or tirzepatide against those who started one of five other diabetes medications: insulin, metformin, a sulfonylurea, an SGLT2 inhibitor, or a DPP4 inhibitor. To reduce the chance that pre-existing differences between groups could explain the results, the researchers used propensity score matching. This statistical technique pairs participants who look similar on a broad range of health and demographic variables, so the comparison becomes more apples-to-apples.
The primary outcome was time to any all-cause overdose event in the 12 months following medication initiation. The researchers used Cox proportional hazards regression, a standard survival analysis tool, to estimate whether the GLP-1 group reached that overdose event sooner or later than the comparison groups.
What the numbers showed
Against two of the five comparison groups, the GLP-1 receptor agonists showed a statistically significant association with lower overdose risk. Compared to insulin, the hazard ratio was 0.32, meaning the GLP-1 group had roughly 68 percent lower observed risk of an overdose event. The sample for that comparison included 630 matched participants. Compared to SGLT2 inhibitors, the hazard ratio was 0.25, suggesting an even larger relative difference, with 432 participants in that matched group.
Against the other three comparators, the picture was different. Compared to metformin, the hazard ratio was 0.75, which was not statistically significant. Against sulfonylureas, it was 0.82, also not significant. And compared to DPP4 inhibitors, the point estimate actually tilted slightly in the other direction at 1.20, again without reaching statistical significance.
The researchers describe this pattern as mixed. The significant results against insulin and SGLT2 inhibitors are intriguing, but the absence of a significant difference when compared to metformin, sulfonylureas, and DPP4 inhibitors complicates a straightforward interpretation.
Why the comparison group matters so much
One of the most important lessons from this kind of study design is that what you use as your comparison group shapes what you conclude. The fact that GLP-1 receptor agonists looked favorable against insulin and SGLT2 inhibitors but not against metformin or sulfonylureas raises a real question: is the effect coming from something unique about GLP-1 receptor agonists, or could some comparison medications themselves carry a higher overdose risk for unrelated reasons?
Insulin, for example, is often prescribed to patients with more advanced or complex diabetes, which can mean a generally higher-risk patient profile. That kind of imbalance is exactly what propensity score matching tries to correct for, but observational data always carries the possibility of residual confounding. The authors acknowledge this directly and emphasize that only randomized controlled trials can fully untangle the relationship.
The proposed biological mechanism
Why might GLP-1 receptor agonists affect overdose risk at all? The working hypothesis in the research literature is that GLP-1 receptors are found not only in the pancreas and gut but also in brain regions associated with reward, motivation, and craving. Preclinical studies in animals have shown that activating these receptors can reduce the reinforcing effects of substances including opioids and alcohol.
The idea is that the same signaling pathway that helps regulate appetite and satiety in metabolic contexts may also modulate dopamine-linked reward circuits. Early observational research in humans had already suggested an association between GLP-1 receptor agonists and reduced opioid overdose rates, and this veterans study was partly motivated by the need to replicate and extend those earlier findings in a different patient population.
It is worth noting that both semaglutide and tirzepatide work through overlapping but not identical mechanisms. Tirzepatide activates both GLP-1 receptors and a second receptor called GIP, which adds another layer of complexity to interpreting the results. The current study combined them into a single comparison group, so it is not possible from this data alone to say whether one performs differently from the other.
Limitations and next steps
The authors are straightforward about the limitations of their work. This is an observational study, not a randomized trial, which means the results can show associations but cannot prove cause and effect. Propensity score matching reduces but does not eliminate the risk that unmeasured differences between groups are driving the results.
The study population is also specific: male-predominant military veterans with both type 2 diabetes and opioid use disorder who were receiving care through the VA system. The literature suggests caution in generalizing these findings to other populations, including younger adults, women, or people without a diabetes diagnosis.
The authors conclude by calling for randomized controlled trials to properly test whether GLP-1 receptor agonists can play a role in treating opioid use disorder. Until that evidence exists, this study is best understood as an important signal that warrants serious follow-up rather than a definitive answer.
Broader research context
This study fits into a wider and rapidly expanding conversation about what GLP-1 receptor agonists might do beyond metabolic regulation. Separate lines of research have examined associations with alcohol use, smoking behavior, and other areas related to reward and impulse. None of these areas yet have the gold-standard randomized trial evidence needed to guide clinical practice, but the volume of early-stage signals is drawing significant scientific attention.
For people interested in the underlying peptide science, the fact that a single receptor class could plausibly influence both metabolic function and reward circuitry reflects how interconnected these biological systems are. Understanding those connections is one of the more active areas in current pharmacology and neuroscience research.
